Rebastinib, CAS 1020172-07-9

Product Description: Rebastinib (DCC-2036) is an orally active, non-ATP-competitive?Bcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.

Applications: Cancer-Kinase/protease

Formula: C30H28FN7O3

References: [1]Chan WW, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 2011, 19(4), 556-568.

CAS Number: 1020172-07-9

Molecular Weight: 553.59

Compound Purity: 99.91

Research Area: Cancer

Solubility: DMSO : 50 mg/mL (ultrasonic;warming;heat to 80°C)

Target: Apoptosis;Bcr-Abl;FLT3;Src

• Artikelnummer: MEXHY-13024-10.1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-13024-10.1
• Verpackungseinheit: 10 mM/1 ml
• Mengeneinheit: STK